

David D'Andrea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7959001/publications.pdf>

Version: 2024-02-01

144
papers

2,535
citations

249298

26
h-index

312153

41
g-index

145
all docs

145
docs citations

145
times ranked

3104
citing authors

#	ARTICLE	IF	CITATIONS
1	Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 367-373.	2.0	22
2	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	1.6	13
3	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	1.3	16
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	2.0	6
5	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>European Urology Focus</i> , 2022, 8, 752-760.	1.6	8
6	Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers. <i>World Journal of Urology</i> , 2022, 40, 1317-1323.	1.2	8
7	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. <i>European Urology Focus</i> , 2022, 8, 1270-1277.	1.6	11
8	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	0.2	15
9	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	1.3	6
10	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	1.2	4
11	Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review. <i>Current Opinion in Urology</i> , 2022, 32, 54-60.	0.9	3
12	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	0.9	3
13	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	1.3	8
14	<i>En Bloc</i> Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.2	26
15	Ischemic Priapism in a 12 Year Old Patient Associated With Coronavirus Disease 2019 (COVID-19): A Case Report. <i>Urology</i> , 2022, 165, 316-318.	0.5	2
16	Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. <i>Cancers</i> , 2022, 14, 887.	1.7	12
17	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	0.8	8
18	Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2022, , 1.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal. <i>Minerva Urology and Nephrology</i> , 2022, 74, 119-121.	1.3	0
20	The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. <i>World Journal of Urology</i> , 2022, 40, 1617-1628.	1.2	28
21	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	0.7	6
22	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
23	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	1.6	10
24	Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 198.e1-198.e9.	0.9	15
25	HUS1 as a Potential Therapeutic Target in Urothelial Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2208.	1.0	0
26	Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. <i>World Journal of Urology</i> , 2022, 40, 1697-1705.	1.2	6
27	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
28	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	1.6	4
29	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. <i>European Urology Open Science</i> , 2022, 41, 74-80.	0.2	2
30	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1067-1074.	1.6	7
31	Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data. <i>European Urology Focus</i> , 2021, 7, 1468-1475.	1.6	92
32	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	1.2	20
33	The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). <i>Clinical Genitourinary Cancer</i> , 2021, 19, 272.e1-272.e7.	0.9	14
34	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	1.2	7
35	Primary Ta high grade bladder tumors: Determination of the risk of progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 132.e7-132.e11.	0.8	9
36	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	0.8	8
38	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 31-36.	0.7	6
39	Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2021, 79, 163-164.	0.9	1
40	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. <i>European Urology Focus</i> , 2021, 7, 124-131.	1.6	31
41	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	1.0	5
42	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
43	Prognostic role of the systemic immune-inflammatory index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	2.0	21
44	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	0.6	5
45	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9
46	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>Eur Urol Focus</i> 2020;6:1233-9. <i>European Urology Focus</i> , 2021, , ,	1.6	0
47	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly - An International Multicenter Study. <i>Bladder Cancer</i> , 2021, 7, 173-185.	0.2	0
48	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 80, 549-563.	0.9	53
49	Differential Prognosis and Response of De novo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2496.	1.7	8
50	The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. <i>Current Opinion in Urology</i> , 2021, 31, 315-323.	0.9	7
51	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.2	5
52	Impact of systemic Immune-inflammatory Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	0.8	14
53	Prognostic value of the systemic immune-inflammatory index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	1.2	18
54	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
56	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
57	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	0.9	27
58	Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. <i>Translational Andrology and Urology</i> , 2021, 10, 4051-4061.	0.6	6
59	Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria. <i>Cancers</i> , 2021, 13, 5377.	1.7	4
60	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. <i>Journal of Personalized Medicine</i> , 2021, 11, 1147.	1.1	1
61	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	2.6	40
62	Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?. <i>Minerva Urology and Nephrology</i> , 2021, 73, 674-676.	1.3	1
63	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	4
64	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	8
65	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
66	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>European Urology Focus</i> , 2020, 6, 1233-1239.	1.6	33
67	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. <i>World Journal of Urology</i> , 2020, 38, 121-128.	1.2	10
68	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 77.e1-77.e7.	0.8	26
69	Response assessment using [⁶⁸ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	1.2	49
70	Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 20-25.e2.	0.9	18
71	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2501-2511.	1.2	9
72	Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 78-87.	0.9	19

#	ARTICLE	IF	CITATIONS
73	En bloc resection for nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 41-47.	0.9	40
74	Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 309-315.	2.0	32
75	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	0.8	3
76	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	1.2	6
77	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	0.8	7
78	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1881-1891.	1.0	8
79	The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy. <i>Arab Journal of Urology Arab Association of Urology</i> , 2020, 18, 213-218.	0.7	7
80	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. <i>Cells</i> , 2020, 9, 1839.	1.8	11
81	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. <i>European Urology Open Science</i> , 2020, 19, 16-19.	0.2	2
82	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2020, 39, 1961-1968.	1.2	10
83	Prognostic models to help predict patient responses to intravesical immunotherapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 243-251.	0.4	1
84	Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. <i>European Urology Focus</i> , 2020, 7, 566-573.	1.6	14
85	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 739.e9-739.e15.	0.8	11
86	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 602.e11-602.e19.	0.8	11
87	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
88	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 52-57.	0.6	4
89	Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 600.e9-600.e15.	0.8	15
90	Ureteral and urethral recurrence after radical cystectomy: a systematic review. <i>Current Opinion in Urology</i> , 2020, 30, 441-448.	0.9	10

#	ARTICLE	IF	CITATIONS
91	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 423-432.	0.8	4
92	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 909-917.	0.2	21
93	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 531-542.	3.9	9
94	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25.	0.8	2
95	A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. <i>BJU International</i> , 2019, 123, 11-21.	1.3	45
96	Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 637-646.	0.8	28
97	Neoadjuvant therapy in urothelial cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 329-333.	0.3	1
98	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
99	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 430-436.	0.8	50
100	Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?. <i>Translational Andrology and Urology</i> , 2019, 8, 85-93.	0.6	14
101	The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 46-53.	0.6	22
102	Second line immune checkpoint inhibition in urothelial cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 414-420.	0.6	3
103	Enhanced Recovery after Radical Cystectomy. <i>Current Opinion in Urology</i> , 2019, 29, 227-238.	0.9	14
104	Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e19-179.e28.	0.8	25
105	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 372-379.	0.8	24
106	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 123-129.	0.8	10
107	Response assessment using ⁶⁸ Ga-PSMA ligand PET in patients undergoing ¹⁷⁷ Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1063-1072.	3.3	100
108	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 959-967.	1.3	63
110	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019, 125, 1449-1458.	2.0	56
111	Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. <i>BJU International</i> , 2019, 123, 646-650.	1.3	35
112	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 97-103.	1.6	3
113	A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 293-305.	0.8	40
114	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e1-158.e6.	0.8	10
115	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e619-e627.	0.9	4
116	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	1.2	71
117	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 347-356.	1.5	12
118	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e73-e78.	0.9	13
119	Biomarkers for immunotherapy in urological cancers. <i>Current Opinion in Urology</i> , 2018, 28, 25-28.	0.9	1
120	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. <i>World Journal of Urology</i> , 2018, 36, 231-240.	1.2	32
121	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 528.e7-528.e13.	0.8	6
122	Tissue biomarkers in nonmuscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 584-590.	0.9	6
123	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 577-583.	0.9	14
124	Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 953.	3.4	51
125	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1981-1995.	1.2	95
126	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 74, 680-681.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1123-e1132.	0.9	19
128	Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 695-703.	1.1	11
129	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. <i>Clinical Cancer Research</i> , 2018, 24, 6300-6307.	3.2	112
130	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018, 101, 197-200.	0.6	12
131	Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. <i>Journal of Surgical Oncology</i> , 2017, 115, 455-461.	0.8	46
132	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e603-e607.	0.9	27
133	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e681-e688.	0.9	9
134	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e1-528.e5.	0.8	14
135	Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. <i>European Urology</i> , 2017, 72, 474-475.	0.9	0
136	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e755-e764.	0.9	29
137	Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 1025-1026.	0.9	0
138	Characteristics and clinical significance of histological variants of bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 651-668.	1.9	147
139	Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>European Urology</i> , 2017, 72, 471-472.	0.9	0
140	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1081-1089.	0.6	42
141	Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. <i>PLoS ONE</i> , 2017, 12, e0182383.	1.1	12
142	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. , 2017, 37, 5747-5753.		5
143	Update on ablative therapies of renal tumors. <i>Current Opinion in Urology</i> , 2016, 26, 410-416.	0.9	13
144	Malignant Perivascular Epithelioid Cell Neoplasm (PEComa) of the Pelvis: A Case Report. <i>Urology Case Reports</i> , 2016, 6, 36-38.	0.1	10